证券代码：603139 证券简称：康惠制药 公告编号：2023-022 陕西康惠制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于参加"2023 年陕西辖区上市公司投资者集体接待日 暨 2022 年度业绩说明会"的公告 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，陕西康惠制药股份有限公 司（以下简称"公司"）将参加由陕西上市公司协会联合深圳市全景网络有限公 司共同举办的"2023 年陕西辖区上市公司投资者集体接待日暨 2022 年度业绩说 明会活动"。 届时，公司董事长及相关高管人员将通过互动平台与投资者进行网络沟通和 交流，欢迎广大投资者踊跃参加！ 二、业绩说明会召开的时间及地点 召开时间：2023 年 5 月 16 日（星期二）15:00-17:00 召开方式：网络在线平台 网络直播地址："全景路演"（http://rs.p5w.net） 重要内容提示： 一、业绩说明会类型 三、参加人员 公司董事长兼总经理、董事会秘书、财务总监及相 ...

Financial Performance - The company reported a net profit attributable to shareholders of -63.06 million yuan for the year 2022, with the parent company achieving a net profit of -40.74 million yuan[5]. - The company will not distribute profits or increase capital reserves for the year 2022, pending approval at the annual shareholders' meeting[5]. - The company's total assets decreased by 2.07% to CNY 1.82 billion in 2022 from CNY 1.86 billion in 2021[21]. - Operating revenue increased by 11.01% to CNY 491.51 million in 2022 compared to CNY 442.76 million in 2021[21]. - The net profit attributable to shareholders was a loss of CNY 63.06 million in 2022, a decline of 272.84% from a profit of CNY 36.48 million in 2021[21]. - The company reported a significant increase in cash flow from operating activities, rising by 579.82% to CNY 50.43 million in 2022 from CNY 7.42 million in 2021[21]. - The weighted average return on equity decreased by 9.81 percentage points to -6.24% in 2022 from 3.57% in 2021[21]. - The first quarter of 2022 saw operating revenue of CNY 117.73 million, with a net profit of CNY 8.79 million attributable to shareholders[23]. - The net profit was -76.78 million yuan, a decrease of 332.70% year-on-year[28]. - Total assets at the end of the reporting period were 1.82 billion yuan, a year-on-year decrease of 2.07%[28]. - Net assets amounted to 1.03 billion yuan, down 7.99% compared to the previous year[28]. Industry Overview - The pharmaceutical manufacturing industry in China generated revenue of 2,911.14 billion yuan in 2022, a year-on-year decrease of 1.6%, and total profit of 428.87 billion yuan, down 31.8% from 2021[12]. - The pharmaceutical industry faces challenges such as rising production costs and intensified competition, but the demand for innovative drugs is expected to grow due to an aging population[12]. - The company operates in a weak cyclical industry, with consistent demand for pharmaceuticals regardless of economic conditions[14]. Company Strategy and Operations - The company focuses on the research, production, and sales of traditional Chinese medicine, with over 100 drug approval numbers and 30 invention patents[15]. - The main products include Compound Shuanghua Tablets and Kunfukang Capsules, which are listed in the national medical insurance directory[15]. - The company emphasizes the importance of traditional Chinese medicine, which is increasingly recognized for its effectiveness and lower side effects compared to Western medicine[13]. - The company has submitted applications for international invention patents and has several patents pending[15]. - The company is committed to enhancing its research and development capabilities to adapt to the evolving pharmaceutical landscape[12]. - The company maintained a diverse sales model, including professional academic promotion and channel distribution, to enhance product reach[19]. - The core products are included in multiple clinical medication guidelines, indicating strong market recognition and efficacy[20]. - The company operates a complete procurement, production, and sales system, ensuring compliance with GMP standards throughout the production process[18]. - The company has established a marketing network across 30 provinces in China, enhancing its market position in various therapeutic areas[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,516[24]. - The largest shareholder, Shaanxi Kanghui Holdings, holds 36.75% of the shares, with a reduction of 2,893,763 shares during the reporting period[24]. - TBP Traditional Medicine Investment Holdings (H.K.) Limited holds 15.80% of the shares, with a reduction of 891,100 shares[24]. - The actual controller, Wang Yanling, directly holds 6.66% of the shares and controls a total of 43.41% of the voting rights[25]. - The company has no preferred shareholders with restored voting rights[25]. - There are no significant changes in the company's operating conditions that would lead to delisting risks[29].

证券代码：603139 证券简称：康惠制药 陕西康惠制药股份有限公司 2023 年第一季度报告 陕西康惠制药股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | 项目 | 本报告期 | 本报告期比上年同期 | | --- | --- | --- | | | | 增减变动幅度(%) | | 营业收入 | 123,792,050.57 | 5.15 | | 归属于上市公司股东的净利润 | 8,206,330.75 | -6.66 | | 归属于上市公司股东的扣除非经常性损益的净利润 | 8,016,925.33 | ...

Financial Performance - The company reported a total operating revenue of CNY 491.51 million for 2022, an increase of 11.01% compared to CNY 442.76 million in 2021[21]. - The net profit attributable to shareholders was a loss of CNY 63.06 million in 2022, a decrease of 272.84% from a profit of CNY 36.48 million in 2021[21]. - The net profit after deducting non-recurring gains and losses was a loss of CNY 66.52 million, a decline of 526.81% compared to a profit of CNY 15.58 million in the previous year[21]. - The company achieved revenue of 490 million yuan in 2022, an increase of approximately 11.01% year-on-year, but reported a net loss of 76.78 million yuan, a decline of 332.70% compared to the previous year[33]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[145]. - The company reported a net profit attributable to shareholders of negative value, resulting in no profit distribution or capital reserve transfer[169]. Cash Flow and Assets - The cash flow from operating activities increased significantly to CNY 50.43 million, up 579.82% from CNY 7.42 million in 2021[21]. - Total assets at the end of 2022 were CNY 1.82 billion, a decrease of 2.07% from CNY 1.86 billion at the end of 2021[21]. - The company's net assets attributable to shareholders decreased by 6.97% to CNY 973.73 million from CNY 1.05 billion in 2021[21]. - The net cash flow from operating activities increased significantly to ¥50,434,200.36, a 579.82% increase compared to the previous year[79]. - Total assets at the end of the reporting period were ¥1,818,000,000, with a significant increase in fixed assets by 73.59% to ¥203,263,985.93[81]. Research and Development - Research and development expenses increased by 21.65% to CNY 12.35 million[61]. - The company’s R&D investment amounted to 12,345.51 million RMB, representing 2.51% of its operating revenue[102]. - The company reported a significant increase in R&D investment for the "Zao Ren An Shen Granules" project, with a 109.67% increase compared to the previous year[103]. - The average R&D investment among comparable companies in the industry was 15,620.26 million RMB, indicating the company's investment is below the industry average[104]. - The company is committed to improving its R&D management system and enhancing the conversion rate of R&D outcomes to achieve strategic goals[129]. Market and Product Strategy - The company plans to continue focusing on its core pharmaceutical business and explore new market opportunities in the future[7]. - The company plans to focus on the steady growth of its traditional Chinese medicine segment and aims for significant growth in the chemical intermediates and active pharmaceutical ingredients segments in 2023[33]. - The company is focusing on expanding its market share for essential medicines, particularly the Xiaoyin Granules, which are included in the national essential medicine list[34]. - The company is actively engaged in the development of new products and technologies to enhance its competitive edge in the pharmaceutical market[41]. - The company aims to enhance its core competitiveness and business scale by focusing on the respiratory, gynecology, orthopedics, dermatology, and diabetes sectors[119]. Governance and Compliance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and protecting shareholder rights[132]. - The board of directors consists of 9 members, including 3 independent directors, ensuring diverse oversight and governance[134]. - The company has established a complete internal control management system in accordance with the Company Law and Securities Law, enhancing governance and protecting investor rights[174]. - The company has a structured remuneration decision-making process for its directors and senior management based on performance evaluations[150]. - The company has committed to not engaging in any competitive business activities that may harm its interests or those of its shareholders[200]. Environmental Responsibility - The company invested 11.6 million yuan in environmental protection during the reporting period[178]. - The actual discharge concentration of wastewater pollutants was COD: 133 mg/L and ammonia nitrogen: 0.3 mg/L, which is below the discharge limits[180]. - The company has implemented a comprehensive wastewater treatment process, ensuring that treated water meets discharge standards before entering the municipal sewage system[182]. - The company has established a mechanism for environmental protection and is recognized as a key pollutant discharge unit, managing its emissions in compliance with regulations[179]. - The company has not faced any environmental disputes or violations and has maintained normal operation of its environmental protection equipment[190]. Challenges and Risks - The company faced significant challenges in 2022 due to a sharp decline in patient visits to medical institutions, impacting business development[31]. - The pharmaceutical industry faces challenges such as rising costs and intensified competition, but the demand for innovative drugs is expected to grow due to an aging population and increasing health awareness[44]. - Fluctuations in the prices of traditional Chinese medicine materials pose a risk to profitability, prompting the company to enhance market monitoring and strategic procurement[127]. - New drug development is characterized by high investment and long cycles, with potential risks if products fail to gain approval or market acceptance[128]. - The competitive landscape in the traditional Chinese medicine industry is intensifying, with many small enterprises facing increased risks due to market price fluctuations and declining drug prices[87].

Financial Performance - The company's operating revenue for Q3 2022 was ¥132,118,911.52, representing a year-on-year increase of 9.25%[4] - The net profit attributable to shareholders decreased by 63.01% to ¥2,339,881.00 for the same period[4] - The basic earnings per share for Q3 2022 was ¥0.02, down 71.43% compared to the previous year[6] - Total operating revenue for the first three quarters of 2022 reached ¥375,140,799.38, an increase of 11.96% compared to ¥335,095,860.67 in the same period of 2021[23] - Net profit for the first three quarters of 2022 was ¥16,131,708.24, a decrease of 19.93% from ¥20,141,367.56 in the same period of 2021[24] - The company reported a total comprehensive income of ¥16,131,708.24 for the period, down from ¥20,141,367.56 in the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,934,892,041.45, an increase of 4.01% from the end of the previous year[6] - As of September 30, 2022, the total assets of the company amounted to RMB 1,934,892,041.45, an increase from RMB 1,860,228,725.79 as of December 31, 2021, reflecting a growth of approximately 3.9%[19] - The company reported a total current liabilities of RMB 378,574,593.81, compared to RMB 318,422,684.80 in the previous year, marking an increase of about 18.9%[19] - The total liabilities of the company amounted to ¥813,525,370.95, an increase from ¥745,202,643.53 in the previous year[21] - The company's total liabilities increased to RMB 378,574,593.81, compared to RMB 318,422,684.80 in the previous year, reflecting an increase of approximately 18.9%[19] Cash Flow - The cash flow from operating activities for the year-to-date increased significantly by 390.29% to ¥46,967,223.22[9] - The net cash flow from operating activities was $46,967,223.22, a significant improvement compared to a net outflow of $16,179,335.15 in the previous period, indicating a positive operational performance[31] - Cash inflow from operating activities totaled ¥437,065,260.94, an increase of 18.93% from ¥367,465,136.03 in the previous year[29] - The cash flow from financing activities generated a net inflow of $68,605,879.86, a decrease from $413,853,902.14 in the previous period, reflecting changes in financing strategies[33] - The cash flow from operating activities showed a positive trend, with cash outflows totaling $390,098,037.72, slightly up from $383,644,471.18, but with improved net cash flow[31] Shareholder Information - The company reported a total of 8,370 common shareholders at the end of the reporting period[11] - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., holds 36.75% of the shares, with 10,000,000 shares pledged[11] - Total equity attributable to shareholders reached ¥1,055,552,796.94, compared to ¥1,046,679,305.61 in the previous year[21] Investments and Subsidiaries - The company established a new subsidiary, Shaanxi Kanghui New Material Technology Co., Ltd., with a registered capital of RMB 3 million, in which it holds a 60% stake[14] - The company's long-term equity investments rose to RMB 141,935,560.11 from RMB 129,401,455.17, showing an increase of approximately 9.5%[17] - The company has made significant investments, with cash paid for fixed assets and other long-term assets amounting to $140,156,681.06, down from $281,219,578.50, reflecting a strategic shift in capital expenditures[31] Expenses - Total operating costs for the first three quarters of 2022 were ¥362,893,894.67, up 14.06% from ¥318,161,562.53 in the previous year[23] - Research and development expenses increased to ¥9,833,820.15, representing a rise of 62.36% compared to ¥6,079,978.65 in the previous year[23]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 243,021,887.86, representing a 13.47% increase compared to CNY 214,168,517.30 in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 9.00% to CNY 13,924,730.33 from CNY 15,301,603.92 year-on-year[21]. - The net cash flow from operating activities significantly improved to CNY 49,227,891.40, compared to a negative cash flow of CNY -10,283,812.22 in the previous year, marking a 578.69% increase[21]. - Basic earnings per share decreased by 6.67% to CNY 0.14 from CNY 0.15 in the same period last year[22]. - The weighted average return on net assets decreased by 0.18 percentage points to 1.32% from 1.50% year-on-year[22]. - The total comprehensive income for the first half of 2022 was CNY 13,833,108.26, compared to CNY 16,431,857.19 in the same period of 2021, indicating a decrease[129]. - The company reported a decrease in profit distribution amounting to CNY 7,391,120.00 during the current period[143]. Assets and Liabilities - The total assets of the company increased by 2.23% to CNY 1,901,696,939.18 from CNY 1,860,228,725.79 at the end of the previous year[21]. - The total liabilities increased to CNY 778,940,506.35 from CNY 745,202,643.53, an increase of about 4.5%[113]. - Current liabilities rose to CNY 392,832,813.52, compared to CNY 318,422,684.80, marking an increase of about 23.3%[111]. - Total liabilities decreased to CNY 554,378,937.69 in the latest report from CNY 562,989,407.91 in the previous period[119]. - The total equity increased to CNY 1,047,979,842.71 from CNY 1,041,537,854.45, indicating a growth of 0.6%[119]. Investment and R&D - The company invested 22.07 million yuan in the drug production base and 1.58 million yuan in the drug research center during the reporting period[48]. - Research and development expenses rose by 19.33% to CNY 4,117,696.81, up from CNY 3,450,669.11, reflecting ongoing investment in innovation[52]. - The company is committed to enhancing its R&D capabilities and has implemented effective risk management mechanisms to ensure the successful achievement of product development goals[65]. Market and Industry Context - The pharmaceutical manufacturing industry in China saw a revenue of CNY 1,400.78 billion in the first half of 2022, a year-on-year decrease of 0.6%[27]. - The total profit of the pharmaceutical manufacturing sector was CNY 220.91 billion in the same period, reflecting a significant year-on-year decline of 27.6%[27]. - The ongoing COVID-19 pandemic has highlighted the unique value of traditional Chinese medicine, presenting new opportunities for industry growth[30]. Product and Sales Strategy - The company focuses on the research, production, and sales of traditional Chinese medicine, with a strong emphasis on developing chemical drug intermediates[29]. - Key products include compound double flower tablets and Kunfukang capsules, which are included in the national medical insurance directory[33]. - The company operates a dual sales model: professional academic promotion for main products and channel distribution for non-main products[37]. - The company has established a marketing network across 30 provinces in China, enhancing its market presence[38]. Environmental Compliance - The company has established wastewater treatment stations at all three production bases, ensuring compliance with municipal wastewater treatment standards[75]. - The company reported no instances of non-compliance with environmental discharge standards during the reporting period[79]. - The company has committed to maintaining its environmental monitoring through third-party assessments, ensuring that all emissions remain within regulatory limits[79]. Corporate Governance and Shareholder Information - The total number of common shareholders as of the end of the reporting period is 8,747[95]. - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., holds 39.65% of the shares, totaling 39,600,000 shares[97]. - The company has not engaged in any major related party transactions during the reporting period[87]. Financial Instruments and Accounting Policies - The company employs a historical cost method for measuring accounting elements, ensuring reliable measurement of financial data[157]. - Financial assets are classified at initial recognition based on the company's management business model and cash flow characteristics, including those measured at fair value and those at amortized cost[172]. - The company applies expected credit loss model for impairment of financial assets measured at amortized cost and certain debt instruments[176].

Financial Performance - In 2021, the company's operating income reached CNY 442,756,905.81, representing a year-on-year increase of 6.93% compared to CNY 414,071,702.69 in 2020[20]. - The net profit attributable to shareholders of the listed company was CNY 36,481,466.06, up 6.94% from CNY 34,113,730.75 in the previous year[20]. - The net profit after deducting non-recurring gains and losses decreased by 42.95% to CNY 15,584,529.04 from CNY 27,317,708.17 in 2020[20]. - The net cash flow from operating activities significantly dropped by 92.08% to CNY 7,418,788.27, compared to CNY 93,722,969.66 in 2020[20]. - Basic earnings per share increased by 8.82% to CNY 0.37 in 2021 from CNY 0.34 in 2020[21]. - The weighted average return on equity rose to 3.57% in 2021, an increase of 0.13 percentage points from 3.44% in 2020[21]. - The net profit attributable to shareholders for Q4 2021 was CNY 14,854,012.34, a significant increase compared to previous quarters[23]. - The company reported a net cash flow from operating activities of CNY 23,598,123.42 in Q4 2021, recovering from negative cash flow in Q1[23]. - The company achieved operating revenue of 442.76 million yuan, an increase of 6.93% year-on-year, and a net profit of 32.997 million yuan, a decrease of 9.49% year-on-year[33]. - The gross profit margin for the pharmaceutical manufacturing segment was 59.09%, a decrease of 1.77 percentage points from the previous year[57]. - Net profit for the period was CNY 32.997 million, a decrease of 9.49% compared to the previous year[54]. - The total number of employees at the parent company and major subsidiaries is 812, with 307 in sales and 217 in production[171]. Assets and Investments - As of the end of 2021, the total assets of the company were CNY 1,860,228,725.79, an increase of 41.87% from CNY 1,311,214,811.94 at the end of 2020[20]. - The net assets attributable to shareholders of the listed company increased by 3.86% to CNY 1,046,679,305.61 from CNY 1,007,732,429.10 in 2020[20]. - The total amount of trading financial assets increased from CNY 55,469,655.31 at the beginning of the year to CNY 119,467,547.42 by year-end, reflecting a change of CNY 63,997,892.11[29]. - The company invested 221.1713 million yuan in the drug production base project and 25.3771 million yuan in the drug research and development center during the reporting period[38]. - The cumulative investment in the drug production base project reached 587.8662 million yuan, while the drug research and development center project reached 42.2002 million yuan by the end of the reporting period[38]. - The company has invested RMB 300 million in Boren Biotechnology, holding an 11.32% stake after the capital increase[106]. - The company’s total assets in its major subsidiaries include RMB 4,775.44 million for Fangyuan Pharmaceutical and RMB 9,467 million for Xinhai Pharmaceutical[112]. Dividends and Shareholder Returns - The company proposed a cash dividend of CNY 0.74 per 10 shares, totaling CNY 7,391,120, which accounts for 20.26% of the net profit attributable to shareholders[6]. - The company has maintained a cash dividend policy, distributing dividends for four consecutive years since its listing, ensuring reasonable returns to shareholders[176]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 196.89 million yuan[144]. Research and Development - Research and development expenses totaled CNY 10.15 million, accounting for 2.29% of total revenue, with no capitalized R&D expenditures[71]. - The number of R&D personnel was 152, making up 18.86% of the total workforce, with a majority aged between 30 and 40 years[72]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing drug efficacy and safety[147]. - The company focuses on R&D in gynecological, orthopedic, and diabetes-related medications, emphasizing market demand and technological innovation[95]. Market Position and Strategy - The company focuses on the pharmaceutical health industry, primarily engaged in the manufacturing of traditional Chinese medicine and chemical drugs, as well as pharmaceutical distribution services[44]. - The company aims to strengthen its market position by focusing on innovative products with high clinical value, which are expected to capture a larger market share[41]. - The company plans to expand its market share in grassroots medical terminals, focusing on products like Zao Ren An Shen Granules and Xiao Yin Granules[88]. - The company is committed to strengthening brand building and improving product market recognition in response to policy changes[88]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for this purpose[198]. Governance and Compliance - The company’s board of directors and management have confirmed the accuracy and completeness of the annual report[5]. - The company maintains independent operations from its controlling shareholder, ensuring no interference in decision-making processes[134]. - The company has implemented effective information disclosure practices, ensuring all shareholders have equal access to information[136]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[135]. - The company has established a comprehensive internal control management system in accordance with relevant laws and regulations, enhancing governance and protecting investor rights[179]. Industry Trends and Challenges - The pharmaceutical industry in China is experiencing stable growth, with increasing health demands and a shift towards high-quality development amid ongoing policy reforms[41]. - The pharmaceutical industry is facing intensified competition and regulatory changes, necessitating a focus on high-quality development and innovation[83]. - The company faces risks from regulatory changes in the pharmaceutical industry, which could impact its operations if not addressed promptly[126]. - The company faces risks from fluctuations in the prices of traditional Chinese medicine materials, which may adversely affect profitability if not effectively managed[130]. Corporate Social Responsibility - The company donated over 100,000 yuan to charitable causes and provided nearly 80,000 yuan worth of medical supplies to local health centers during the reporting period[188]. - The company has invested in pollution control facilities and monitoring systems to ensure compliance with environmental standards, with no incidents of non-compliance reported[186].

Financial Performance - The company's operating revenue for Q1 2022 was ¥117,729,916.33, representing a year-on-year increase of 21.68%[4] - The net profit attributable to shareholders was ¥8,791,930.72, showing a decrease of 3.44% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥7,837,432.34, which is an increase of 8.51% year-on-year[4] - The net profit for the first quarter of 2022 was CNY 9,153,640.00, an increase of 9.25% compared to CNY 8,376,450.68 in the same period of 2021[25] - The total profit for the first quarter of 2022 was CNY 11,263,451.56, up from CNY 10,452,555.93 in Q1 2021, reflecting a growth of 7.75%[25] - Operating profit for the first quarter of 2022 reached CNY 11,419,086.29, compared to CNY 10,580,400.70 in Q1 2021, indicating an increase of 7.95%[25] - The total comprehensive income for the first quarter of 2022 was CNY 9,153,640.00, compared to CNY 8,376,450.68 in Q1 2021, reflecting an increase of 9.25%[27] Cash Flow - The net cash flow from operating activities reached ¥24,685,902.03, a significant increase of 235.92% compared to the previous year[4] - Cash flow from operating activities generated a net amount of CNY 24,685,902.03, a significant improvement from a net outflow of CNY 18,162,009.79 in the previous year[30] - Cash flow from investing activities resulted in a net outflow of CNY 66,682,283.18, compared to a net outflow of CNY 150,943,959.82 in Q1 2021, showing a reduction in cash outflow[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,838,053,085.62, down 1.19% from the end of the previous year[4] - Total assets as of March 31, 2022, amounted to ¥1,838,053,085.62, slightly down from ¥1,860,228,725.79 at the end of 2021[21] - Total liabilities decreased to ¥713,873,363.36 from ¥745,202,643.53 at the end of 2021, a reduction of 4.2%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,634[11] - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., holds 39.65% of the shares and is subject to a pledge of 900,000 shares[11] Costs and Expenses - Total operating costs for Q1 2022 were ¥106,722,145.56, up from ¥87,868,202.45 in Q1 2021, reflecting a growth of 21.4%[23] - The company's financial expenses surged by 240.70%, primarily due to increased interest expenses on bank loans[7] - Research and development expenses increased to ¥1,445,540.79 in Q1 2022 from ¥1,309,336.56 in Q1 2021, showing a rise of 10.4%[23] Inventory and Receivables - Inventory as of March 31, 2022, was ¥117,081,713.09, a slight decrease from ¥119,892,500.02 at the end of 2021[16] - The company reported a significant increase in accounts receivable, which rose to ¥154,257,777.92 from ¥146,142,009.87, indicating a growth of 5.3%[16] Cash and Equivalents - Cash and cash equivalents as of March 31, 2022, were ¥162,546,662.27, down from ¥203,959,902.14 at the end of 2021, a decrease of 20.3%[16] - The company reported cash and cash equivalents at the end of Q1 2022 amounting to CNY 142,546,662.27, down from CNY 437,073,631.33 at the end of Q1 2021[32] Earnings Per Share - Earnings per share remained stable at CNY 0.09 for both basic and diluted earnings per share in Q1 2022[27] Credit Impairment - The company incurred a credit impairment loss of CNY -2,239,461.45 in Q1 2022, compared to CNY -407,830.56 in the same period of 2021, indicating a significant increase in credit losses[25]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 陕西康惠制药股份有限公司 2021 年第三季度报告 证券代码：603139 证券简称：康惠制药 陕西康惠制药股份有限公司 2021 年第三季度报告 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 120,927,343.37 | 4.23 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 214,168,517.30, representing a 21.38% increase compared to CNY 176,437,773.64 in the same period last year[20]. - The net profit attributable to shareholders of the listed company decreased by 5.94% to CNY 15,301,603.92 from CNY 16,267,248.48 year-on-year[20]. - Basic earnings per share decreased by 6.25% to CNY 0.15 from CNY 0.16 in the same period last year[21]. - The net profit for the company was 14.31 million yuan, a year-on-year decrease of 19.63%[39]. - The company's operating revenue for the reporting period was CNY 214,168,517.30, representing a 21.38% increase compared to CNY 176,437,773.64 in the same period last year[46]. - The net profit for the first half of 2021 reached ¥16.43 million, compared to ¥13.35 million in the first half of 2020, indicating a year-over-year increase of approximately 23.5%[112]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of CNY 10,283,812.22, a 55.10% reduction from CNY 22,902,641.51 in the previous year[20]. - The company's cash and cash equivalents increased by 66.58%, reaching CNY 324,691,580.12 compared to CNY 194,910,699.25 at the end of the previous year[48]. - The company's cash flow from operating activities showed a net outflow of approximately ¥10.28 million in the first half of 2021, an improvement from a net outflow of ¥22.90 million in the same period of 2020[114]. - The total cash and cash equivalents at the end of the period increased to 270,385,112.60 RMB, up from 221,857,593.78 RMB in the previous year[119]. Assets and Liabilities - Total assets increased by 30.83% to CNY 1,715,448,903.60 compared to CNY 1,311,214,811.94 at the end of the previous year[20]. - Total liabilities increased to CNY 636,288,351.16 from CNY 238,273,951.19, which is an increase of approximately 167.5%[98]. - The total equity of the company as of June 30, 2021, was CNY 1,079,160,552.44, slightly up from CNY 1,072,940,860.75 at the end of 2020, showing a marginal increase of about 0.6%[98]. - The company's total assets at the end of the reporting period were 1,079,160,552.44 RMB, showing growth from the previous year[125]. Investment and Development - The total investment in the pharmaceutical production base project reached CNY 42,209.12 million, with an additional CNY 5,539.63 million invested during the reporting period[50]. - The pharmaceutical R&D center project accumulated an investment of CNY 1,885.65 million, with CNY 203.34 million invested in the current period[50]. - The company is in the trial production phase for its subsidiary Shaanxi Youbang, with expectations to officially start production by the end of Q3[40]. - Research and development expenses for the first half of 2021 were CNY 3,450,669.11, compared to CNY 2,788,388.16 in the same period of 2020, marking a rise of 23.7%[104]. Market Position and Products - The company focuses on the pharmaceutical health industry, primarily engaged in the research, production, and sales of traditional Chinese medicine, with 19 invention patents and over 100 drug production approvals[23]. - Major products include Compound Shuanghua Tablets, Kunfukang Capsules, and Xiaoyin Granules, all listed in the national medical insurance directory, indicating strong market presence[24]. - The company has established a strong market position in gynecology, dermatology, and orthopedics, with its products being recommended in clinical treatment guidelines[28]. - The company's core products include Kunfukang capsules, Fufang Shuanghua tablets, and Xiaoyin granules, which are included in the National Medical Insurance Directory[36]. Governance and Compliance - There were no significant changes in the company's governance or major risks identified during the reporting period[22]. - The company maintained compliance with environmental regulations, with no incidents of exceeding emission standards reported during the period[71]. - The company has not faced any significant lawsuits or arbitration matters during the reporting period[73]. - The company has committed to maintaining its environmental responsibilities and has implemented measures to ensure compliance with pollution control standards[71]. Financial Management and Strategy - The company has a clear policy for terminating financial asset recognition, which helps in maintaining accurate financial records[156]. - The company assesses credit risk of financial instruments at each balance sheet date, determining if there has been a significant increase in credit risk since initial recognition[162]. - The company uses derivative financial instruments to hedge against currency, commodity price, and interest rate risks, measuring them at fair value[166]. - The company’s financial strategy includes a focus on both cash flow generation and potential asset sales, indicating a balanced approach to financial management[158]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,739[82]. - The largest shareholder, Shaanxi Kanghui Holdings, held 39,600,000 shares, accounting for 39.65% of total shares[84]. - The company did not distribute dividends or issue bonus shares for the reporting period[65]. - The company did not experience any changes in share capital structure during the reporting period[81].